Other
Amyloid
2
Pipeline Programs↗
3
Active Trials↗
5
Companies Involved↗
Amyloid is an early-stage landscape with 2 programs across 5 companies. The most active players are Johnson & Johnson, AstraZeneca, Mindful Diagnostics and Therapeutics, LLC.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 1
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
2programs
Small molecule150%
Monoclonal antibody150%
Modality classified for 100% of 2 pipeline programs.
Analysis
Trial Status
29
clinical trials
Completed19 · 66%
Terminated5 · 17%
Not yet recruiting2 · 7%
Unknown status1 · 3%
Withdrawn1 · 3%
Recruiting1 · 3%
Clinical Trials
Trial Activity
29 trials
Amyloid Lowering for Alzheimer's in Down's With Donanemab Investigation
Not yet recruiting·—·Phase 4·NCT06911944·60 enrolled
Serum Amyloid A Protein And Fetuin A Levels
Completed·—·N/A·NCT02433405·60 enrolled
Page 1 of 2
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)